Charles River Acquires Agilux

Boston – October 11, 2016 – Cooley advised Charles River Laboratories on its acquisition of Agilux Laboratories for $64 million. 

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions accelerate their research and drug development efforts. Agilux is a contract research organization that provides a suite of integrated discovery small and large molecule bioanalytical services, drug metabolism and pharmacokinetic services and pharmacology services.

“Agilux reinforces the linkage between our discovery and safety assessment capabilities, and provides clients with a comprehensive testing solution that spans their discovery and regulated drug development needs,” said James Foster, CEO of Charles River in a company press release.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. 

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.